Investors
Value-Generating Platform
By creating products that customers desire, LOVE Pharma can produce significant value for shareholders.
Corporate Information
LOVE Pharma is a future-looking company in an ever-changing industry, offering innovative products through disruptive technologies that target mental and sexual health.
- Significant near and mid-term growth catalysts – 7.2% CAGR over the next 10 years (nutraceuticals)
- Investing in sustainable, long-term revenue with proven products, technologies, and established sales performance
- Retail ready products for cross-channel promotion to include DTC, brick & mortar, MLM, closed networks, white labeling, and others
- 6 exclusively licensed technologies
- Experienced, long-term, drug and nutraceutical team
- Domestic and international expansion
Capital Structure
Common Shares Outstanding
312,169,945
Options for Common Shares
nil
Warrants for Common Shares (not listed)
73,626,130
Fully Diluted Shares Outstanding
385,796,075
Financials
Financial Statements
Please find the company's financial statements and management discussion and analysis at the issuers profile on SEDAR
Corporate Governance
Highlights
Oct 2020
Signed initial licensing agreements for novel products
Feb 2020
Closed an initial $2,600,000 CAD in funding
Dec 2020
Signed exclusive licensing partnership with pharmaceutical company
April 2020
Filed patent in partnership with pharmaceutical company for the delivery of psilocybin in a psychedelic mucoadhesive strip
May 2021
Partnered with Potent Ventures to launch Bloom in the US market
Sept 2021
Listed on the Canadian Stock Exchange